512 — Grand Pharmaceutical Share Price
Last trade - 00:00- HK$20.28bn
- HK$21.99bn
- HK$11.64bn
- 62
- 70
- 90
- 88
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 9.36 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -7.14% | ||
| Dividend Yield (f) | 4.46% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.25 | ||
| Price to Tang. Book | 1.57 | ||
| Price to Free Cashflow | 16.08 | ||
| Price to Sales | 1.76 | ||
| EV to EBITDA | 8.15 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 15.66% | ||
| Return on Equity | 15.61% | ||
| Operating Margin | 24.77% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | HK$m | 6,352.92 | 8,597.98 | 9,562.28 | 10,529.59 | 11,644.89 | 12,157.5 | 13,249.5 | 12.06% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +50.16 | +31.54 | -12.67 | +6.7 | +10.25 | -13.34 | +8.2 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Grand Pharmaceutical Group Ltd, formerly China Grand Pharmaceutical and Healthcare Holdings Ltd is a Hong Kong-based investment holding company principally engaged in the manufacturing and sales of pharmaceutical preparations and medical devices. The Company is principally engaged in manufacturing and sales of pharmaceutical preparations and medical devices, bio-technology products, nutrition products, specialized pharmaceutical raw materials and other products. The main products of the Company cover the anti-tumor, cardiovascular emergency pharmaceutical products and advanced cerebro-cardiovascular intervention advanced medical devices, anti-virus and anti-infection, respiratory and ear-nose-throat (ENT), bio-health products and specialized pharmaceutical ingredients.
Directors
- Xiao Feng Shi CHM (48)
- Chao Zhou CEO (31)
- Zhanqi Niu EDR (54)
- Yan Shao EDR (58)
- Weikun Tang EDR (36)
- Yonghua Feng OTH (53)
- Zhi Qiang Qian OTH (52)
- Guofan Xie OTH (70)
- Tin Chung Foo SEC (52)
- Yebi Hu NID (57)
- Geng Pei NID (61)
- Tosi Wan So NID (58)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 18th, 1995
- Public Since
- December 19th, 1995
- No. of Employees
- 11,987
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 3,501,809,500
- Address
- Units 3302
- Web
- https://www.grandpharma.cn/
- Phone
- +852 28663718
- Auditors
- HLB Hodgson Impey Cheng
Upcoming Events for 512
Similar to 512
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 20:55 UTC, shares in Grand Pharmaceutical are trading at HK$5.86. This share price information is delayed by 15 minutes.
Shares in Grand Pharmaceutical last closed at HK$5.86 and the price had moved by +37.56% over the past 365 days. In terms of relative price strength the Grand Pharmaceutical share price has outperformed the FTSE Developed Asia Pacific Index by +39.13% over the past year.
The overall consensus recommendation for Grand Pharmaceutical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Grand Pharmaceutical dividend yield is 4.44% based on the trailing twelve month period.
Last year, Grand Pharmaceutical paid a total dividend of HK$0.26, and it currently has a trailing dividend yield of 4.44%.Looking ahead, the next dividend pay date is 2025-04-28.
We do not have data on when Grand Pharmaceutical is to next pay dividends. The historic dividend yield on Grand Pharmaceutical shares is currently 4.44%.
To buy shares in Grand Pharmaceutical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$5.86, shares in Grand Pharmaceutical had a market capitalisation of HK$20.28bn.
Here are the trading details for Grand Pharmaceutical:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 512
Based on an overall assessment of its quality, value and momentum Grand Pharmaceutical is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Grand Pharmaceutical is HK$6.78. That is 15.72% above the last closing price of HK$5.86.
Analysts covering Grand Pharmaceutical currently have a consensus Earnings Per Share (EPS) forecast of HK$0.61 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Grand Pharmaceutical. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +31.56%.
As of the last closing price of HK$5.86, shares in Grand Pharmaceutical were trading +21.75% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Grand Pharmaceutical PE ratio based on its reported earnings over the past 12 months is 9.36. The shares last closed at HK$5.86.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Grand Pharmaceutical's management team is headed by:
- Xiao Feng Shi - CHM
- Chao Zhou - CEO
- Zhanqi Niu - EDR
- Yan Shao - EDR
- Weikun Tang - EDR
- Yonghua Feng - OTH
- Zhi Qiang Qian - OTH
- Guofan Xie - OTH
- Tin Chung Foo - SEC
- Yebi Hu - NID
- Geng Pei - NID
- Tosi Wan So - NID